News | Women's Health | September 13, 2016

UCLA Study Finds Common Breast Cancer Test Not Cost-Effective

Results indicate Oncotype Dx DCIS score reduces proportion of population undergoing adjuvant radiation, but clinicians and patients must decide if benefit is worth increased cost

UCLA study, Oncotype Dx DCIS test, breast cancer, cost-effectiveness

September 13, 2016 — A new study by a University of California Los Angeles (UCLA) researcher has found that a genomic test widely used to help determine whether women with a common form of breast cancer should undergo radiation is not cost effective. The study was conducted by Ann C. Raldow, M.D., assistant professor in residence in the Department of Radiation Oncology at UCLA and member of the UCLA Jonsson Comprehensive Cancer Center, in collaboration with colleagues at Harvard and University of Texas Southwestern.

The study was published online in the Journal of Clinical Oncology.

The Oncotype Dx DCIS test is given to patients with ductal carcinoma in situ (DCIS) to improve treatment selection by better identifying the biological potential of tumors to recur. Medicare reimburses about $3,400 dollars for the Oncotype Dx DCIS test.

Using a standard willingness-to-pay threshold of $100,000 per-quality-adjusted-life-year, implementing the Oncotype Dx DCIS was not cost effective. However, the researchers noted that implementing the Oncotype Dx DCIS score would reduce the proportion of the population undergoing adjuvant radiation, thus decreasing the number of women at risk for potential side effects. Whether this benefit is sufficient to justify the increased cost should be debated.

DCIS comprises approximately 25 percent of breast cancers, and over 60,000 women are diagnosed with it in the United States each year. One of the treatment goals for patients with DCIS is to minimize the risk of a local recurrence while maximizing breast conservation. While radiation carries a chance of side effects that may reduce the quality of a patient's life, observation carries the chance of an increased risk of recurrence. Despite the significant number of patients with the disease, the risks and optimal treatment remain unknown, resulting in difficulties with clinical decision-making.

Previous research has demonstrated the ability of the Oncotype Dx DCIS test to predict the 10-year risk of developing an ipsilateral breast event (a local recurrence of the DCIS or an invasive carcinoma) in patients with DCIS treated with breast conserving surgery without radiation therapy. These results suggest that the Oncotype Dx DCIS test may have potential for selecting women who may be treated with surgery alone with omission of radiation treatment.

The research team used a mathematical tool called a Markov model that was informed by the published literature and Medicare claims to determine the cost-effectiveness of using the Oncotype DX DCIS test among women most routinely considered candidates for observation following breast-conserving surgery. 

The author reports no external funding for this study.

For more information: www.jco.ascopubs.org

Related Content

Novel Technique May Significantly Reduce Breast Biopsies
News | Breast Biopsy Systems | January 17, 2019
A novel technique that uses mammography to determine the biological tissue composition of a tumor could help reduce...
Digital Mammography Increases Breast Cancer Detection
News | Mammography | January 16, 2019
The shift from film to digital mammography increased the detection of breast cancer by 14 percent overall in the United...
MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Artificial Intelligence Used in Clinical Practice to Measure Breast Density
News | Artificial Intelligence | January 15, 2019
An artificial intelligence (AI) algorithm measures breast density at the level of an experienced mammographer,...
Sponsored Content | Videos | Breast Imaging | January 11, 2019
Supplemental screening with ABUS helps personalize breast care for women with dense breasts and offers advanced...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer
News | Brachytherapy Systems | January 04, 2019
Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity...
Breast Cancer Patients Have Less Heart Damage With Heart Drug and Trastuzumab
News | Cardio-oncology | January 03, 2019
Breast cancer patients who take a heart drug at the same time as trastuzumab have less heart damage, according to a...
RayStation 8B Released With Machine Learning Applications for Treatment Planning
Technology | Treatment Planning | December 27, 2018
RaySearch Laboratories released RayStation 8B, the latest version of the radiation therapy treatment planning system (...
Opto-Acoustic Imaging Helps Differentiate Breast Cancer Molecular Subtypes
News | Ultrasound Women's Health | December 20, 2018
Seno Medical Instruments Inc. (Seno Medical) reported results of a study demonstrating that morphologic and functional...